ARVN ▲ +2.9% - Arvinas, Inc.
$ARVN - Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease
07-OCT-2026 07:00 AM ET
Share this post
More filings for $ARVN
ARVN ▼ -4.0% - Arvinas, Inc.Oct 1, 2026ARVN ▼ -0.1% - Arvinas, Inc.Sep 29, 2026ARVN ▲ +0.8% - Arvinas, Inc.Sep 28, 2026ARVN ▼ -2.7% - Arvinas, Inc.Sep 3, 2026ARVN ▲ +0.7% - Arvinas, Inc.Sep 1, 2026ARVN - Arvinas, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 15, 2026
View full $ARVN filing history →💬 Comments
Loading comments…
Leave a comment